Email Alert | RSS

北京大学学报（医学版） ›› 2021, Vol. 53 ›› Issue (6): 1094-1098. doi: 10.19723/j.issn.1671-167X.2021.06.015

• 论著 • 上一篇    下一篇

树突状细胞疫苗特异肿瘤多肽联合树突状细胞体外刺激淋巴细胞功能评估

杨朵1,周心娜1,王硕1,王小利1,袁艳华1,杨化兵1,耿会珍2,彭兵2,李子博2,李彬2,任军1,△()   

  1. 1.首都医科大学附属北京世纪坛医院肿瘤内科,肿瘤治疗性疫苗北京市重点实验室,北京 100038
    2.河北博海生物工程开发有限公司,石家庄 050035
  • 收稿日期:2021-02-04 出版日期:2021-12-18 发布日期:2021-12-13
  • 通讯作者: 任军 E-mail:jun.ren@duke.edu;renjun@bjsjth.edu.cn
  • 基金资助:
    河北省创新能力提升计划项目国际科技合作基地建设专项(19392411D)

Assessment of lymphocytic function in vitro stimulated by specific tumor polypeptide combined with dendritic cells

YANG Duo1,ZHOU Xin-na1,WANG Shuo1,WANG Xiao-li1,YUAN Yan-hua1,YANG Hua-bin1,GENG Hui-zhen2,PENG Bing2,LI Zi-bo2,LI Bin2,REN Jun1,△()   

  1. 1. Department of Oncology, Beijing Shijitan Hospital, Capital Medical University Beijing Key Laboratory of Therapeutic Vaccines, Beijing 100038, China
    2. Hebei Bio-High Technology Company Limited, Shijiazhuang 050035, China
  • Received:2021-02-04 Online:2021-12-18 Published:2021-12-13
  • Contact: Jun REN E-mail:jun.ren@duke.edu;renjun@bjsjth.edu.cn
  • Supported by:
    Special Project for the Construction of International Science and Technology Cooperation Base of Hebei Innovation Capability Improvement Plan Project(19392411D)

RICH HTML

   

PDF (PC)

摘要：

目的:利用树突状细胞(dendritic cell,DC)作为抗原递呈载体,检测树突状细胞疫苗特异肿瘤多肽在体外对淋巴细胞是否有刺激增殖、促进细胞因子分泌及促进对肿瘤细胞的杀伤功能。方法:外周血树突状细胞和细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)分离及培养采用贴壁法;采用CCK-8法检测淋巴细胞增殖功能;酶联免疫斑点法检测淋巴细胞的细胞因子分泌功能;CCK-8法检测淋巴细胞对肿瘤细胞的杀伤功能。实验分为肿瘤多肽组(肽+DC-CIK)、DC-CIK组和单纯CIK组进行各项功能检测与比较。结果:在白介素-2(interleukin-2,IL-2)存在时, 3组细胞均增殖明显。肿瘤多肽组在第4天、第6天(第4天Z=-3.79, P<0.001;第6天Z=-2.95, P<0.01)时,450 nm光密度显著高于CIK组,在第4天时,450 nm光密度显著高于DC-CIK组(Z=-2.02, P<0.05)。培养体系中无IL-2时,各组淋巴细胞均增殖缓慢,各时间点光密度差异无统计学意义。肿瘤多肽刺激组多种细胞因子产生量高于单纯CIK组,其中白介素-4(interleukin-4,IL-4)(Z=-2.61, P<0.01)、巨噬细胞集落刺激因子(granulocyte-macrophage colony-stimulation factor, GM-CSF)(Z=-3.85, P<0.001)、干扰素-γ(interferon-γ, IFN-γ)(Z=-3.56, P<0.001)和肿瘤坏死因子-α(tumor necrosis factor-α, TNF-ɑ, Z=-3.40, P<0.001)的分泌量与单纯CIK组相比,差异均有统计学意义。肿瘤多肽刺激组与DC-CIK组相比,除IL-4分泌量差异有统计学意义外(Z=-2.15, P<0.05), 其余各项细胞因子分泌量差异均无统计学意义。DC-CIK组与单纯CIK组相比,IFN-γ(Z=-2.44, P<0.05)、TNF-ɑ(Z=-2.26, P<0.05)和GM-CSF(Z=-3.73, P<0.001)分泌量差异有统计学意义。肿瘤多肽组与DC-CIK组、单纯CIK组在18 h与24 h的杀伤效率虽然差异无统计学意义,但有高于其他两组的趋势。结论:树突状细胞疫苗特异肿瘤多肽联合树突状细胞体外可提高CIK细胞的增殖活性,提高多个细胞因子的分泌量。

关键词: 树突状细胞, 肿瘤多肽, CIK细胞, 增殖, 细胞因子, 杀伤

Abstract:

Objective: To assess the activation function of specific tumor polypeptide for dendritic cell vaccine on lymphocytes proliferation, production of cytokines and killing activity in vitro by using dendritic cells as antigen presenting vector. Methods: Peripheral blood dendritic cells (DC) and cytokine-induced killer (CIK) were isolated and cultured by adherent culture method; CCK-8 method was used to assess the proliferation function of lymphocytes and the killing function of lymphocytes to tumor cells; enzyme-linked immunospot assay method was used to evaluate the secretion function of cytokines. The experiment was divided into tumor polypeptide group (peptide with DC-CIK), DC-CIK group and CIK group. Results: With presence of interleukin-2 (IL-2) in the culture system, the lymphocyte proliferation of the three groups was obvious. The absorbance at 450 nm of tumor polypeptide group was significantly higher than that of CIK group at the time points day 4 and day 6 (day 4: Z=-3.79, P<0.001; day 6: Z =-2.95, P< 0.01). The absorbance at 450 nm of group tumor polypeptide was significantly higher than that of DC-CIK group on day 4 (Z=-2.02, P<0.05). Without IL-2 in the culture system, lymphocytes proliferated slowly in all the three groups, and there was no significant difference in 450 nm absorbance at each time point. The levels of IL-4 (Z=-2.61, P< 0.01), granulocyte-macrophage colony-stimulation factor (GM-CSF, Z=-3.85, P< 0.001), interferon- γ (IFN- γ, Z=-3.56, P< 0.001) and tumor necrosis factor-α (TNF-ɑ, Z=-3.40, P< 0.001) of tumor polypeptide group were higher than those of CIK group. There was no significant difference in the production of cytokines except IL-4 (Z=-2.15, P< 0.05) when tumor polypeptide group was compared with DC-CIK group. The production of IFN-γ (Z=-2.44, P<0.05), TNF-ɑ (Z=-2.26, P< 0.05) and GM-CSF (Z=-3.73, P< 0.001) in DC-CIK group were higher than those of CIK group. Although there was no significant difference in killing activity between tumor polypeptide group, DC-CIK group and CIK group at hour 18 and hour 24, and the killing activity of tumor polypeptide group was higher than that of the other two groups. Conclusion: Tumor peptide combined with dendritic cells can improve the proliferation activity of CIK cells in vitro, and increase the secretion of several cytokines.

Key words: Dendritic cells, Tumor polypeptides, CIK cells, Proliferation, Cytokines, Cytotoxicity

中图分类号: 

  • R73-36+2

表1

患者一般信息及肿瘤特异多肽检测结果"

Serial number Gender Age/years Clinical diagnosis and stage Number of tumor specific
polypeptides*		 Polypeptide target
organ#		 Target cell△
1 Female 58 NSCLC stage Ⅳ 8 Lung A549
2 Male 59 Gastric cancer stage Ⅳ 4 Stomach SGC-7901
BGC-823
3 Female 57 Gastric cancer
stage Ⅳ		 6 Stomach SGC-7901
BGC-823
4 Male 64 Bladder cancer
stage Ⅳ		 3 Bladder TCCSUP
5 Female 73 Mammary cancer stage Ⅳ 5 Breast MCF-7
6 Female 56 NSCLC stage Ⅳ 6 Lung A549
7 Male 60 NSCLC stage Ⅳ 6 Lung A549
8 Female 46 NSCLC stage Ⅳ 8 Lung A549
9 Female 73 Pancreatic cancer stage Ⅳ 5 Pancreas CFPAC-1
10 Female 53 TNBC stage Ⅳ 6 Breast MDA-MB-453
11 Male 46 Colonic metastasis of gastric cancer stage Ⅳ 6 Colon HCT-116

图1

肿瘤多肽刺激淋巴细胞增殖情况"

图2

不同组细胞因子的分泌量"

图3

不同效应细胞/靶细胞比共孵育18 h(A)及24 h(B)各组CIK细胞对肿瘤细胞的杀伤效率"

[1] 黄芸, 高建鹏, 王辉. 肿瘤疫苗临床研究评价及进展[J]. 肿瘤学杂志, 2019, 25(3):196-201.
[2] 沈季敏, 刘欣. 基于树突状细胞的肿瘤免疫治疗临床应用方式的研究进展[J]. 临床血液学杂志, 2018, 31(1):62-65.
[3] 邵小钧, 席庆. 精准医疗: 肿瘤诊治的新模式[J]. 现代肿瘤医学, 2016, 24(4):675-677.
[4] Jang GY, Kim YS, Lee SE, et al. Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors[J]. Cancer Immunol Immunother, 2021, 70(4):1075-1088.
doi: 10.1007/s00262-020-02759-6
[5] Jiang N, Qiao G, Wang X, et al. Dendritic cell/cytokine-induced killer cell immunotherapy combined with s-1 in patients with advanced pancreatic cancer: A prospective study[J]. Clin Cancer Res, 2017, 23(17):5066-5073.
doi: 10.1158/1078-0432.CCR-17-0492 pmid: 28611200
[6] Calmeiro J, Carrascal MA, Tavares AR, et al. Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview[J/OL]. Pharmacol Res, 2021, 164: 105309[2021-01-01]. https://doi.org/10.1016/j.phrs.2020.105309.
[7] Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy[J/OL]. Nat Commun, 2019, 10(1): 5408[2021-01-01]. https://doi.org/10.1038/s41467-019-13368-y.
[8] 黄聪, 白丽. 树突状细胞肿瘤疫苗及其联合应用的研究进展[J]. 细胞与分子免疫学杂志, 2019, 35(12):1141-1145.
[9] Zhou JY, Alvarez CA, Cobb BA, Integration of IL-2 and IL-4 signals coordinates divergent regulatory T cell responses and drives therapeutic efficacy[J/OL]. Elife, 2021, 10: e57417(2021-02-22)[2021-03-01]. https://doi.org/10.7554/eLife.57417.
[10] 于甜, 胡小鹏, 祝小红, 等. 干扰素及肿瘤坏死因子抗病毒作用研究进展[J]. 中国免疫学杂志, 2014, 30(3):409-415.
[11] 马守宝, 林丹丹, 刘海燕. 炎症细胞因子在肿瘤微环境中的作用及其作为治疗靶点的研究进展[J]. 生命科学, 2016, 28(2):182-191.
[12] 林雨虹, 吕合作, 吴俊英. GM-CSF/IL-3/IL-5的免疫调节作用[J]. 中国免疫学杂志, 2019, 35(4):500-504.
[13] 姜南雁, 唐隽, 徐云升. GM-CSF在肿瘤免疫治疗中的作用最新研究进展[J]. 免疫学杂志, 2015, 31(8):717-722.
[14] 吴晋楠, 陈建荣, 陈金亮, 等. 肺癌肿瘤微环境中白细胞介素的研究进展[J]. 临床肺科杂志, 2019, 24(12):2280-2283.
[15] 李琬琼, 高艳锋. 抗肿瘤多肽药物研究进展[J]. 药学进展, 2019, 43(10):759-766.
[1] 田佳宜, 郭一学, 张霞, 孙晓麟, 何菁. 中国健康成人外周血自然杀伤细胞及其亚群的正常值范围流式细胞学分析[J]. 北京大学学报（医学版）, 2024, 56(5): 839-844.
[2] 刘家骏, 刘国康, 朱玉虎. 免疫相关性重症肺炎1例[J]. 北京大学学报（医学版）, 2024, 56(5): 932-937.
[3] 张瑶,郭金鑫,战世佳,洪恩宇,杨慧,贾安娜,常艳,郭永丽,张璇. 富含半胱氨酸和甘氨酸蛋白2在神经母细胞瘤恶性进展中的功能和机制[J]. 北京大学学报（医学版）, 2024, 56(3): 495-504.
[4] 赵祥格,刘佳庆,黄会娜,陆智敏,白自然,李霞,祁荆荆. 干扰素-α介导系统性红斑狼疮外周血CD56dimCD57+自然杀伤细胞功能的损伤[J]. 北京大学学报（医学版）, 2023, 55(6): 975-981.
[5] 刘媛,原婉琼,李婷,王平章,吕平,吴利新,阮国瑞,韩文玲,莫晓宁. 敲减CMTM3增加急性B淋巴细胞白血病细胞对伊马替尼敏感性[J]. 北京大学学报（医学版）, 2022, 54(6): 1238-1243.
[6] 蒋青,张雨. 新形势下运动损伤特点及细胞生物治疗的应用前景和挑战[J]. 北京大学学报（医学版）, 2021, 53(5): 828-831.
[7] 马向波,张学武,贾汝琳,高颖,刘洪江,刘玉芳,李英妮. 外周血淋巴细胞亚群检测在系统性硬化症治疗中的应用[J]. 北京大学学报（医学版）, 2021, 53(4): 721-727.
[8] 王子乔,刘燕鹰,张霞,刘田,任立敏,沈丹华,王屹,栗占国. 17例误诊为IgG4相关疾病患者的临床特点及误诊原因分析[J]. 北京大学学报（医学版）, 2019, 51(6): 1025-1031.
[9] 谢静,赵玉鸣,饶南荃,汪晓彤,方滕姣子,李晓霞,翟越,李静芝,葛立宏,王媛媛. 3种口腔颌面部来源的间充质干细胞成血管内皮分化潜能的比较研究[J]. 北京大学学报（医学版）, 2019, 51(5): 900-906.
[10] 朱红林,杜倩,谌威霖,左晓霞,李全贞,刘思佳. 系统性硬化症血清细胞因子表达谱变化及调控机制[J]. 北京大学学报（医学版）, 2019, 51(4): 716-722.
[11] 张帆,燕太强,郭卫. Rasfonin抑制骨肉瘤细胞143B的增殖和迁移[J]. 北京大学学报（医学版）, 2019, 51(2): 234-238.
[12] 刘佳兴,胡贵平,赵琳,张永明,王丽,贾光,刘瑞祥,冯慧敏,徐华东. 铬酸盐低水平长期职业接触与劳动者早期健康效应[J]. 北京大学学报（医学版）, 2019, 51(2): 307-314.
[13] 季兰岚,郝燕捷,张卓莉. 原发性骨髓纤维化引起的继发性痛风1例[J]. 北京大学学报（医学版）, 2018, 50(6): 1117-1119.
[14] 王子成，程立，吕同德，苏黎，林健，周利群. 炎症因子预处理的脂肪干细胞可明显抑制外周血单个核细胞增殖[J]. 北京大学学报(医学版), 2018, 50(4): 590-594.
[15] 唐旭，赵卫红，宋琴琴，殷华奇，杜依青，盛正祚，王强，张晓威，李清，刘士军，徐涛. SOX10对前列腺癌细胞增殖及侵袭的影响[J]. 北京大学学报(医学版), 2018, 50(4): 602-606.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部